Full Press Release Details
Technologies Appoints New Members to Board of Directors
and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth
ANTONIO, Texas (August 18, 2025) - bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company
advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto
Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors.
Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase
sales of CyPath Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria
Zannes, President and CEO of bioAffinity Technologies.
Rios brings more than four decades of executive leadership in corporate finance and governance across industries including biotechnology,
medical devices, and large-scale construction. He held financial leadership roles at ILEX Oncology, BioMedical Enterprises and Bartlett
Cocke General Contractors and currently serves on the boards of CCC Group and Stem Cell Reserve. His proven track record in guiding companies
through growth, capital strategy, and operational excellence will strengthen bioAffinity Technologies' financial foundation.
Oppenheimer is the Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University
of Medicine and Dentistry of New Jersey-Rutgers. He is a leader in the diagnosis and treatment of asthma and COPD and an advisor to pharmaceutical
companies focused on lung health. He has participated in more than 180 clinical studies and authored more than 260 publications and led
or contributed to numerous clinical guidelines. Dr. Oppenheimer has served in leadership positions with the American Board of Allergy
and Immunology, the American Academy of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology.
His extensive clinical experience will help guide bioAffinity's scientific and clinical strategies, particularly in advancing its
companion diagnostics in the pipeline for the growing asthma therapeutics market estimated at $26 billion.
Technologies also announced that Gary Rubin stepped down from the Board of Directors for personal reasons and not due to any disagreement
with the Company or its operations, policies or practices. "We are grateful to Gary for his valuable contributions to bioAffinity
over the past seven years and appreciate his continued support," Ms. Zannes said.
Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that
indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung
incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results
demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high
risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve
outcomes and increase patient survival. For more information, visit www.cypathlung.com.
bioAffinity Technologies, Inc.
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT)
by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe," "expect,"
"anticipate," "estimate," "continue," "predict," "forecast," "project,"
"plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements
regarding the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members
of the Board of Directors. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult
to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied
by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members
of the Board of Directors and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December
31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking
statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and
conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not
to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release,
and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.